Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2025-12-27 @ 5:50 PM
Study NCT ID:
NCT04629703
Status:
COMPLETED
Last Update Posted:
2023-08-18
First Post:
2020-11-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Sponsor:
Rigel Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
C-935788-061
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None